A hallmark of cancer is aberrant DNA methylation, consisting of global hypomethylation and regional hypermethylation of tumor suppressor genes. DNA methyltransferase inhibitors have been recognized as promising candidate anticancer drugs. Drug development has focused on DNA methylation inhibitors with the goal of activating tumor suppressor genes silenced by DNA methylation. 5-azacytidine (5-AC; Vidaza), a global DNA methyltransferase inhibitor, was Food and Drug Administration approved to treat myelodysplastic syndromes and is clinically tested for solid tumors. In this paper, it was demonstrated that 5#-aza-2#-deoxycytidine (5-azaCdR) activated both silenced tumor suppressor genes and pro-metastatic genes by demethylation, raising the concern that it would promote metastasis. 5-AzaCdR treatment increased the invasiveness of non-invasive breast cancer cell lines MCF-7 cells and ZR-75-1 and dramatically induced pro-metastatic genes; Urokinase plasminogen activator (uPA), matrix metalloproteinase 2 (MMP2), metastasis-associated gene (H-MTS1; S100A4) and C-X-C chemokine receptor 4 (CXCR4). The hypothesis that the blocking of cellular transformation activity of DNA methyltransferase inhibitor could be separated from the pro-metastatic activity was tested using short interfering RNA (siRNA) targeted to the different DNA methyltransferase (DNMT) genes. Although depletion of DNMT1 had the strongest effect on colony growth suppression in cellular transformation assays, it did not result in demethylation and activation of uPA, S100A4, MMP2 and CXCR4 in MCF-7 cells. Depletion of DNMT1 did not induce cellular invasion in MCF-7 and ZR-75-1 non-invasive breast cancer cell lines. These data have implications on the design of new DNA methyltransferase inhibitor and on the proper utilization of current inhibitors.
Introduction
DNA methylation is a covalent modification of DNA that plays an important role in gene expression programming. Disruption of DNA methylation patterns could lead to disease by disruption of normal physiological gene expression programs. Cancer has been the first disease where DNA methylation was proposed as a therapeutic target (1) . Three types of aberration in the DNA methylation machinery occur in cancer: hypermethylation of tumor suppressor genes, aberrant expression of DNA methyltransferase (DNMT) 1 and other DNMTs as well as hypomethylation of unique genes and repetitive sequences (2) (3) (4) . The expression of DNMT1 is tightly regulated with the state of cell growth by transcriptional and posttranscriptional mechanisms (5) (6) (7) (8) (9) . Several oncogenic pathways lead to overexpression of DNMT1 through transcriptional and posttranscriptional control of DNMT1 (10) (11) (12) (13) . Deregulation of the proper cell cyclecoordinated expression of DNMT1 causes cellular transformation (11) . Other studies have shown that overexpression of DNMT1 in non-transformed cells leads to cellular transformation (14) , whereas knockout of DNMT1 protects mice from colorectal cancer (15) . Taken together, these data support the idea that inhibition of DNMT1 should be a reasonable strategy for anticancer therapeutics. The anticancer effects of DNMT1 inhibition were demonstrated both pharmacologically using antisense oligonucleotide inhibitors (16, 17) and genetically using Dnmt1À/À mice (15) .
Screens for hypomethylated genes in different cancers revealed several genes that were characteristically unmethylated in different types of cancer (18, 19) . In addition to activation of gene expression through promoter demethylation, hypomethylation causes genomic instability (20) and unleashes the expression of repetitive sequences disrupting gene expression programming (21) . These data suggest that demethylation could result in promotion of oncogenesis and metastasis. Experimental support for this idea was provided by showing that mice bearing dnmt1 hypomorphic alleles developed thymic lymphomas (22) .
The first DNA methylation inhibitor 5-azacytidine (AC; Vidaza) (23) was recently approved by the Food and Drug Administration for treatment of myelodysplastic syndromes (24) . Vidaza is now considered a new and promising approach to cancer therapy. It is a prodrug that is phosphorylated to the triphosphate nucleotide, 5-aza-2#deoxycytidine (5-azaCdR), and incorporated into DNA during DNA synthesis. DNMT1 forms a covalent bond with the carbon at position 6 of the 5-azaCdR ring, trapping the DNMT on the nascent strand of DNA (25) . The replication fork progresses in the absence of DNMT, resulting in passive loss of DNA methylation in the extending nascent strand (25) . However, since 5-azaCdR was reported to cause demethylation in non-dividing neurons (26) , it was possible that 5-azaCdR would also acted through a different mechanism that did not require incorporation of 5-azaCdR into replicating DNA, such as triggering proteasomal degradation of DNMT (27) . 5-AzaCdR blocks DNMT globally and is not DNMT gene specific. In addition to activating tumor suppressor genes, which results in blocking of cancer growth, 5-azaCdR also demethylates and activates pro-metastatic genes such as Heparanase (28) and Urokinase plasminogen activator (uPA), which play an important role in metastasis (29, 30) . The methylation state of uPA has been indeed investigated in the past in surgical biopsy samples from breast cancer patients at different grades. uPA expression and demethylation was correlated with increasing malignancy and invasiveness (31) . Similarly, uPA is methylated in normal prostate epithelial cells and demethylated in invasive prostate cancer cell lines (32) . It is possible, however, that uPA is silenced in some non-invasive breast cancer cells by mechanisms that do not involve DNA methylation. 5-AzaCdR forms adducts with DNA and has toxic effects independent of DNA demethylation (33) . Therefore, it is plausible that 5-azaCdR induces pro-metastatic genes by a DNA demethylation/DNMT-independent mechanism. This combination of properties of 5-azaCdR poses the challenge of identifying new strategies to target tumor suppressor genes and block cancer growth with DNMT inhibitors while avoiding the activation of prometastatic genes and precluding the danger of cancer metastasis. We tested whether it was possible to separate the inhibition of cellular transformation from the activation of metastasis by genespecific depletion of DNMT. Three DNMTs encoded by different genes are known to participate in generating and maintaining the DNA methylation pattern: DNMT1 (34), DNMT3a and DNMT3b (35) . Since DNMT1 was shown to be particularly involved in controlling cell growth (11, 36, 37) , we were interested to determine whether specific inhibition of DNMT1 would increase the selectivity toward inhibition of cellular transformation and reduce the risk of increasing cell invasiveness by DNMT-dependent and -independent effects observed with the non-specific DNMT inhibitor 5-azaCdR. The implications of these results on future DNMT inhibition-based therapeutics will be discussed.
Materials and methods

Cell culture
Human non-invasive breast cancer cells MCF-7 and ZR-75-1, invasive breast cancer cells MDA-MB-231 and normal breast epithelial cells MCF10A were purchased from American Type Culture Collection (ATCC, Manassas, Virginia). MCF-7 cells were cultured in minimum Eagle's medium with 10 lg/ml of insulin (Invitrogen, Carlsbad, California). ZR-75-1 cells were cultured in RPMI1640 (Invitrogen). MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen). All media were supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin. MCF10A cells were cultured in Mammary Epithelial Basal Media (MEGMÒ; Lonza/Clonetics Corporation, Basel, Switzerland) supplemented with the BulletKitÒ provided by the manufacturer. The GA-1000 (gentamycin-amphotericin B mix) from the BulletKitÒ was not added to the media as recommended by ATCC. MCF-7 and ZR-75-1 cells were treated with 1 or 5 lm 5-azaCdR (Sigma, St. Louis, MO) for 1 or 6 days with medium replaced every day to maintain drug concentration.
RNA interference transfections
Short interference RNA toward DNMT1, DNMT3a and DNMT3b, were ordered from one of the siGENOME SMARTpoolÒ sequences provided by Dharmacon, (Lafayette, Colorado). Scrambled control was used as control (target sequence ordered: scrambled control 5#-GCCUUGGCAGCCUAGGC-GA-3#, siDNMT1 5#-GGAAGAAGAGUUACUAUAA-3#, siDNMT3A 5#-GCACUGAAAUGGAAAGGGUUU-3# and siDNMT3b 5#-GAAAGUAC-GUCGCUUCUGAUU-3#). A blast search indicated that each short interfering RNA (siRNA) specifically targeted the cognate DNMT gene, including all the known splice variants. Twenty-four hours prior to treatment, cells were plated at a concentration of 1 Â 10 5 cells, in a 10 cm tissue culture dish. To prepare a transfection mixture for a 10 cm plate culture; 15 ll Lipofectin (Invitrogen) were added to 100 ll of serum-free Opti-modified Eagle's medium (MEM) and the mixture was incubated for 30 min. This lipid mixture was then added to a mixture of siRNA (280 pmol) in 60 ll of Opti-MEM. The lipid/siRNA mixture was incubated for 20 min and Opti-MEM was added to top up the volume to a total of 4 ml. The 4 ml mixture was added to cells that were washed twice with phosphate-buffered saline (PBS) prior to transfection. After 4 h incubation, the oligonucleotide-containing Opti-MEM was removed from the cells and replaced with regular growth medium. Combinations of several siRNAs were transfected in the same manner. The final concentration of each siRNA was 70 nM. The cells were transfected three times over a period of 6 days, the same length as of time as the 5-azaCdR treatment.
Quantitative real-time polymerase chain reaction Reverse transcription was performed using 3 lg of RNA and 20 U of reverse transcriptase (Roche, Basel, Switzerland) as recommended by the manufacturer. Two microliters of complementary DNA were used in a 20 ll reaction with SYBR green mix, 0.5 lM forward and reverse primers (Table I for description of primers). The reaction was performed in a Roche LightCycler LC480 using the following conditions: a denaturation step lasting 10 min at 95°C was followed by 45 repeats of the following cycle: 95°C for 10 s, annealing at the appropriate temperature for 10 s and extension at 72°C for 10 s. Following the 45th cycle, we performed a final extension step at 72°C for 10 min. For quantification and normalization, the results were analyzed by the Roche LightCycler 480 software.
Western blots
Nuclear proteins were extracted from the cells in a buffer containing 20 mM Tris, 0.5 mM ethylenediaminetetraacetic acid, 0.5 mM dithiothreitol, 25% glycerol and 1.5 mM MgCl 2 , 0.5 mM phenylmethylsulfonyl fluoride and 0.4 M NaCl. Whole-cell proteins were extracted in RIPA buffer (1% NP40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate in PBS) in the presence of protease inhibitors (Complete; Invitrogen). The protein concentrations for each sample were determined using the standard Bradford assay. Twenty micrograms of nuclear proteins or 50 lg of whole-cell protein were subjected to denaturing and reducing electrophoresis on 7.5% Tris-glycine polyacrylamide gels. Proteins were then electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked (1 h, room temperature) with Carnation dried milk (5 or 10%) in Tris-buffered saline with Tween 20 (TBST) (Tris, NaCl and 0.1% Tween 20, pH 7.6) and incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% milk. Primary antibodies used were anti-DNMT1 (1:1000, ab13537; Abcam, Cambridge, MA), anti-DNMT3a (1:200, ab4897; Abcam) or anti-DNMT3b (1:200; ab16049; Abcam). The membranes were washed twice with TBST and then incubated (1 h, room temperature) with horseradish peroxidase-conjugated sheep anti-mouse or anti-rabbit IgG antibody (1:5000 or 1:3000, respectively; Amersham Biosciences, Uppsala, Sweden). After three 10 min long washes with TBST, the proteins were visualized using a chemiluminescence kit (Renaissance kit) and were exposed to BioMax imaging film (Kodak, St. Louis, MO). The membranes were then stripped and were reprobed using anti-a/b tubulin (1:1000, #2148; Cell Signaling Technology, Danvers, MA) to control for equal loading.
Boyden chamber Matrigel invasion assay
Cell invasion assays were performed following the manufacturers protocol (Chemicon, Billerica, MA). Briefly, 3 Â 10 5 cells in serum-free media were plated for each treatment condition in the upper chamber containing the Matrigel-coated membranes. Serum-containing media acted as chemo-attractants in the lower chambers. After incubation for 48 h, the invaded cells at the bottom of the membrane were stained and counted under a light microscope with a Â400 magnification. All experiments were performed in triplicates.
Proliferation assay
Cells that were treated with 5-azaCdR or siRNAs for 6 days were plated at a concentration of 5 Â 10 4 in six-well plates in triplicate. At specific time points (24, 72 and 120 h), the cells were trypsinized and stained with trypan blue. Viable cells were counted under a light microscope. All experiments were performed in triplicate.
Soft agar assay Cells (3 Â 10 3 ) treated with 5-azaCdR or siRNAs were resuspended into single-cell suspension in 3 ml of medium. One milliliter of 1.5% pre-warmed Bacto Agar (BD Science, Franklin Lakes, NJ) was mixed with the cells and plated into a six-well plate in triplicate. The colonies that formed on the soft agar matrix were counted under a light microscope after 2 weeks.
Pyrosequencing Sodium bisulfite-treated DNA was subjected to polymerase chain reaction (PCR) amplification using biotinylated primers as described previously (38) . Twenty-five microliters of the PCR products were used to perform pyrosequencing in PyroMark 
Nearest neighbor analysis
Global methylation at CG dinucleotides was determined by nearest neighbor analysis as described previously (39) . This assay measures the state of methylation of Cs residing upstream to GATC sequences in DNA (MboI cuts at GATC sites). Genomic DNA was digested with MboI. The GATC sticky end left after digestion with MboI was filled in with a labeling reaction containing radioactive [a-
32 P] dGTP and non-radioactive deoxyadenosine triphosphate, dTTP, deoxycytidine triphosphate and the Klenow fragment of DNA polymerase I. The 32 P-labeled DNA was digested by micrococcal nuclease (Sigma) and spleen phosphodiesterase (Worthington Biochemical Corporation, Lakewood, NJ). These enzymes cleave out 3# mononucleotides; therefore, the labeled 32 P that was introduced into the DNA by the [a- Effects of specific DNMT gene depletion
Flow cytometry
The effects of the different treatments on cell cycle kinetics were determined by Flow cytometry analysis of propidium iodide-labeled cells. Cells were fixed by adding drop wise, 70% of ice-cold ethanol. The fixed cells were kept at 4°C until used. Fixed cells were washed with PBS and then treated with 1 U of DNase-free RNase. Propidium iodide (0.5 mg) was added to stain the cells overnight. Flow cytometry analysis was performed on a flow cytometer (FACS Calibur). Results were analyzed further using the FlowJo Software.
Thymidine incorporation Cells were pulsed with 1 lCi/ml [ 3 H] thymidine for 5 h and were then washed with PBS five times. PBS washed cells were incubated in 10% trichloroacetic acid at 4°C overnight, before being washed twice with 5% trichloroacetic acid for 30 min. The cells were lysed with 1% sodium dodecyl sulfate in 1 N NaOH, and the level of [ 3 H] thymidine incorporation was measured in a liquid scintillation counter.
Statistics
Student's t-tests were performed to determine the statistical significance of the results. All the treatments were compared with the related control conditions. The significance threshold is set at P-value ,0.05 and is indicated by asterisks ( Ã ).
Results
The effect of depletion of specific DNMT genes on triggering invasiveness in a human non-invasive breast cancer cell line We have shown previously that 5-azaCdR treatment of non-invasive breast cancer cell lines resulted in increased invasiveness in vitro and in vivo through induction of pro-metatastic genes such as uPA (40) . We repeated this observation in Figure 1A . Since 5-azaCdR is a global DNMT inhibitor, we reasoned that the effects of 5-azaCdR on cell invasion require downregulation of either a specific DNMT protein or a combination of DNMT proteins. To address this question, we depleted the different DNMT messenger RNAs (mRNAs) with siRNAs that were specific for the different DNMT genes (DNMT1, DNMT3a and DNMT3b), using either a single or different combinations of DNMT siRNAs. mRNA and protein levels were quantified by quantitative PCR and western blot analyses after treatment. These analyses presented in Figure 1B showed effective depletion of the specific DNMT mRNAs ( Figure 1B ) under all treatment conditions. There was some cross talk between the DNMTs that was observed in our study. Depletion of DNMT3b also reduced DNMT3a mRNA and protein. Interestingly, depletion of DNMT1 reduced the levels of DNMT3b protein, without affecting mRNA levels. DNMT1 and 3b proteins are known interacting partners (41) and cooperate in regulating DNA methylation and gene expression in cancer (42, 43) . Therefore, despite the specificity in the siRNA target sequence, downregulation of one protein might, to a certain extent, affect the level of other DNMT proteins. In any case, the effect of the specific mRNA was more pronounced. In 5-azaCdR-treated cell, DNMT1, 3b mRNA and protein levels were downregulated, whereas DNMT3a was the least affected by the treatment. This observation was consistent with previous studies, which showed that 5-azaCdR treatment decreased 44) . The enhanced reduction of DNMT3b levels observed in our study might be due to the longer treatment time of the drug. We have also compared the protein levels of different DNMTs in MCF-7 to normal breast epithelial cells MCF10A and to a more invasive breast cancer cell line MDA (supplementary Figure 1 is available at Carcinogenesis Online). MDA has been shown to have overall higher DNMT activities than MCF-7 cells and normal breast cells (45) . Indeed, we observed higher levels of DNMTs in the most malignant cell line MDA. We then measured the effect of each of the specific DNMT depletions on expression of five pro-metastatic genes that are normally not expressed in the non-invasive breast cancer cell line MCF-7. The results presented in Figure 1C showed that whereas 5-azaCdR dramatically induced the expression of uPA, MMP2, heparanase (HPSE), metastasis-associated genes (H-MTS1; S100A4) and C-X-C chemokine receptor 4 (CXCR4), these genes were not induced by the single DNMT depletions with the exception of siDNMT3b depletion that induced the CXCR4 gene. A combination of DNMT depletions resulted in reexpression of the pro-metastatic genes to a different extent; however, none of these effects were comparable with the effects of 5-azaCdR treatment ( Figure 1C) .
We then measured invasiveness using Boyden Matrigel chamber assay and demonstrated that depletion of DNMT1 by itself did not result in any increase in cell invasiveness. The same was true for the other DNMT single depletions. However, a combination of depletions of DNMT1 and DNMT3b and the triple depletion resulted in induction of the invasive capacity of the non-invasive breast cancer cell line MCF-7 cells that was more similar to the one triggered by the pan DNMT inhibitor 5-azaCdR ( Figure 1D ). DNMT3a did not seem to contribute to the invasiveness triggered by pan inhibition of DNMTs, which was consistent with the smaller effect of 5-azaCdR on depletion of the DNMT3a protein ( Figure 1B lower panel) . The impact of combination treatments on expression of the five pro-metastatic genes did not completely correspond to increased invasiveness. A combination of DNMT1 and DNMT3a depletion induced three of five prometastatic genes ( Figure 1C) while it failed to induce invasion. This implied that other events induced by a combination of DNMT1 and DNMT3a inhibition were more critical for triggering cell invasiveness than induction of these genes alone. In summary, our study illustrated that specific depletion of individual DNMT alone did not result in induction of either pro-metastatic genes or invasion. A combination of DNMT genes depletion did recapitulate the effect of 5-azaCdR ( Figure 1D ), suggesting that the mixed effect of 5-azaCdR on cell growth and cell invasiveness could be isolated and differentiated when specific DNMT genes are targeted.
Blocking cell growth by specific depletion of DNMT genes We then tested whether inhibition of specific DNMT genes would be sufficient to produce a significant effect in growth suppression. We Effects of specific DNMT gene depletion measured the induction of p21, a growth control gene that was shown previously to be induced in A549 cells by DNMT1 depletion between 2-and 3-fold (46) . A recent study has also shown that p21 was induced upon DNA damage triggered by 5-azaCdR treatment (47) . Our results showed that although single depletion of DNMTs resulted in a slight induction in p21 in MCF-7 cells, full induction of p21 to the level achieved by 5-azaCdR was also seen in the combination of DNMT1 and DNMT3a depletion as well as depletion of all three DNMTs (Figure 2A) . Cell growth inhibition, as measured by increase in cell number, was triggered with any of the single DNMTs ( Figure 2B ). The growthinhibiting effects were further supported by cell cycle analysis ( Figure 2C and D) . Single DNMT1 depletion reduced thymidine incorporation as early as 24 h after treatment, which was consistent with previous studies that had shown S-phase arrest in response to DNMT1 depletion (36,48) ( Figure 2C ). Depletion of DNMT3b reduced thymidine incorporation into DNA at a slower rate, while there was no effect of DNMT3a depletion ( Figure 2C ). Correspondingly, DNMT1 depletion reduced the number of cells found in the S-phase of the cell cycle, 24 h post initiation of treatment, as determined by flow cytometry. This inhibition remained stable at later time points ( Figure 2D ). There was again no effect of DNMT3a inhibition. These results demonstrated the distinct effects of specific DNMT inhibition on cell growth, DNA synthesis and cell cycle kinetics.
The most important result was that the maximal blockage of anchorage-independent growth, a measure of cellular transformation in vitro, was achieved when DNMT1 was singularly depleted ( Figure 2E ). A combination of DNMT depletions did not enhance this effect ( Figure 2E ). Thus, specific depletion of DNMT1 resulted in a strong suppression effect on cellular transformation ( Figure 2E ), while it had no effect on cell invasiveness ( Figure 1D ).
Effects of specific DNMT depletion on global DNA demethylation
One of the characteristics of cancer cells is global DNA hypomethylation (4), suggesting that global hypomethylation might be of advantage for cancer cells and that global demethylation might have a deleterious effect on therapy. 5-AzaCdR treatment had a profound impact on the global state of DNA methylation ( Figure 3A) . Interestingly, in contrast to 5-azaCdR, single DNMT depletion, including a combination of all three DNMT depletions, caused only limited global DNA demethylation ( Figure 3A ). DNMT1 and DNMT3b depletion caused a slight reduction of global methylation levels while no effect was seen with DNMT3a depletion.
Interestingly, even a triple DNMT gene depletion did not trigger the level of loss of DNA demethylation seen with 5-azaCdR ( Figure 3A) . What was striking was that in the case of 5-azaCdR, global demethylation occurred in spite of the fact that the DNA synthesis was inhibited at 24 h ( Figure 2C ). How did 5-azaCdR treatment result in demethylation in the absence of new DNA synthesis? One possible answer is that 5-azaCdR triggered a replication-independent DNA demethylation process. To test this hypothesis, we determined whether DNA demethylation in the presence of 5-azaCdR continued after 48 h, a time point at which both DNA synthesis (measured by thymidine incorporation in Figure 2C ) and cell growth (measured by trypan blue assay in Figure 3B ) were stopped. The results of a nearest neighbor analysis shown in Figure 3C indicated that global demethylation was enhanced between day 3 and 4, long after DNA synthesis and cell growth were blocked. This result supported the idea that 5-azaCdR unleashed a DNA replication-independent DNA demethylation.
Effects of specific DNMT gene depletion on site-specific DNA demethylation 5-AzaCdR caused demethylation of several pro-metastatic gene promoters such as uPA and MMP2 ( (40), Figure 4) . We tested by pyrosequencing, whether single DNMT depletion would result in demethylation of the different CG sites in these promoters and whether combination of two or three DNMT gene depletions would increase the extent of demethylation. We also determined whether any combination of DNMT depletions conferred site selective DNA Ã P-value ,0.05.
F.Chik and M.Szyf demethylation. Our results showed a very limited demethylation of CG sites in both the uPA and MMP2 promoters with single DNMT depletions ( Figure 4A and B) . This was consistent with the lack of induction of these genes by single DNMT depletion ( Figure 1C) . Nevertheless, our results revealed certain site selectivity with the specific single DNMT depletions. For example, CG site number 5 at the uPA promoter was slightly demethylated in response to DNMT1 depletion and not DNMT3a and DNMT3b depletions. There was even larger selectivity when combinations of DNMT depletions were involved. The triple combination had the largest effect on all CG sites in the uPA promoter ( Figure 4A ). However, there was not a single example in the uPA promoter where the triple depletion approached the extent of demethylation with 5-azaCdR (except site 5). The genespecific demethylation followed the same trend of the global hypomethylation seen in Figure 3A . The combination of DNMT1 and DNMT3a showed the lowest level of DNA demethylation in all uPA CG sites. The DNA demethylation in the MMP2 promoter induced by 5-azaCdR was not as dramatic. Similar to the results obtained with the uPA promoter, the combinations of depletions of all DNMTs exhibited the highest levels of DNA demethylation that approached the levels seen with 5-azaCdR. These results demonstrated that combinations of DNMT depletions resulted in some selectivity in the demethylated sites.
Effects of specific DNMT depletion on induction of pro-metastatic genes, cell invasiveness, cell growth and promoter methylation in non-invasive ZR-75-1 human breast cancer cells We then determined the cell specificity of DNMT gene-specific depletions. In Figure 5A , we showed that expression of either uPA, MMP2, HPSE, S100A4 or CXCR4 was turned on with 5-azaCdR but not with either of the DNMT depletion combinations. Cell invasion was induced by single depletion of DNMT3a but not DNMT1 or DNMT3b depletions ( Figure 5B) . A triple depletion combination significantly increased invasion. When cell transformation was measured, DNMT1 depletion had the strongest inhibitory effect and that was not enhanced by a triple depletion ( Figure 5C ). A smaller effect was seen with DNMT3b depletion but not with DNMT3a depletion. The methylation status of uPA and MMP2 promoters was measured by pyrosequencing ( Figure 5D) . Surprisingly, despite the reactivation of the uPA gene by 5-azaCdR treatment in this cell line as seen in a previous study (40) and in Figure 5A , the promoter of the uPA gene had very low methylation even in the untreated cells. On the other hand, the MMP2 promoter was more methylated in the untreated cells. Interestingly, DNMT1 depletion had the most pronounced effect on DNA methylation. Yet, the demethylation caused by single DNMT1/ triple DNMTs depletion did not reflect the expression patterns of Data were obtained from at least three independent experiments; Ã P-value ,0.05 for the specific CpG site.
Effects of specific DNMT gene depletion the gene ( Figure 5A ). Perhaps a detailed examination of a wider promoter region would have identified the methylation-dependent regulatory elements of these genes in ZR-75-1 cells. Alternatively, 5-azaCdR might have affected the expression of MMP2 and uPA in ZR-75-1 cells indirectly through methylation-independent mechanisms. In summary, ZR-75-1 cells, similar to MCF-7 cells, displayed distinct effects of specific DNMT depletion, and the effects on cell invasion and cell transformation were nicely separated. While DNMT1 depletion had a strong effect on cell transformation, there was no effect on cell invasiveness. DNMT3a inhibition on the other hand had no effect on cell transformation ( Figure 5C ) but it increased cell invasion ( Figure 5B ). DNMT3a depletion, therefore, increased the adverse effects and had no beneficial effects, whereas DNMT1 depletion exhibited beneficial effects without the adverse effect of increased cell invasiveness. This experiment also illustrated that although general rules apply to both MCF-7 and ZR-75-1 cells, there were cell type differences as well. For example, a triple DNMT depletion resulted in induction, albeit limited, of uPA in MCF-7 cells ( Figure 1C ) but not in ZR-75-1 cells ( Figure 5A) . A single depletion of DNMT3a induced invasiveness in ZR-75-1 cells ( Figure 5B ) but not in MCF-7 cells ( Figure 1D ).
Discussion
Although DNMT inhibition is a promising therapeutic strategy in cancer and possibly other diseases, the main challenge comes from the realization that pan DNMT inhibition could result in activation of pro-metastatic genes. This raises the concern that DNMT inhibition would trigger metastasis, one of the most morbid aspects of cancer. 5-AzaCdR, a member of the family of the first approved DNA methylation drugs, induces pro-metastatic genes and triggers a dramatic increase in cell invasiveness (Figure 1 ). We hypothesized that these effects are due to the non-selective nature of 5-azaCdR and, therefore, if selective inhibitors of DNMT genes would be used, it might be possible to separate the antigrowth from the pro-metastatic consequences of DNMT inhibition. This hypothesis implies that the different DNMT genes have distinct roles in different cellular functional pathways, such as cell growth and invasiveness. We tested this hypothesis using a non-invasive human breast cancer cell line MCF-7 and single or a combination of specific siRNAs for the different DNMT genes. Taken together our data supports this hypothesis. Whereas DNMT1 depletion inhibits anchorage-independent growth, it does not increase cell invasiveness. Thus, it is possible to separate the cell transformation activity Figure 4 . Data were obtained from a triplicate pyrosequencing analysis of DNA prepared from two independent experiments; Ã P-value ,0.05 for the specific CpG site compared to its state of methylation in untreated cells.
F.Chik and M.Szyf of DNMT inhibitors from the adverse effects such as increased invasiveness. Our study predicts that selective DNMT1 inhibitors would effectively reverse cellular transformation and block tumor growth without increasing cell invasiveness. Our data also shows that combined inhibition of DNMTs does not enhance the inhibition of cellular transformation but significantly induces cell invasiveness ( Figure 1D ). Not all combinations are identical, for example the combination of DNMT1 and DNMT3b depletion triggers invasiveness but not the combination of DNMT1 and DNMT3a. This suggests selectivity in the combination of DNMTs that control genes involved in cell invasiveness in MCF-7 cells. Interestingly, the selectivity extends to each of the different parameters that we studied here from siteselective demethylation to differential effects on pro-metastatic gene expression, DNA synthesis, cell growth and cellular transformation. For example, there is no immediate linear correlation between the effects of depletion of specific DNMTs on uPA expression and invasiveness, suggesting that additional gene-circuitries are involved.
The two non-invasive breast cancer cell lines tested in our study exhibited some differences in their response to DNMT inhibition. First, even a triple depletion of DNMTs failed to induce uPA in ZR-75-1 cells ( Figure 5A ), which was different than the situation in MCF-7 cells where a triple combination induced this gene ( Figure 1C) . Second, single depletion of DNMT3a was sufficient to induce invasiveness in ZR-75-1 ( Figure 5C ), but not in MCF-7 ( Figure 1D ). However, in both cell lines, single depletion of DNMT1 had the strongest effect on cell transformation and no effect on cell invasiveness, supporting a primary and general role for DNMT1 as an anticancer target (37) .
Interestingly, uPA is induced by 5-azaCdR in ZR-75-1 cells even though the promoter of this gene is unmethylated ( Figure 5D ). There are several possible explanations. First, uPA is suppressed in ZR-75-1 cells by a mechanism that does not involve DNA methylation and that 5-azaCdR induces the gene by a DNA methylation-independent mechanism. Adducts of aza-DNMT-DNA are formed at the replication forks and they were reported to have toxic effects (33) . It is possible that 5-azaCdR-DNA adducts affect gene expression as well. The possibility that 5-azaCdR induced uPA in a DNA methylationindependent manner in ZR-75-1 cells is further supported by the observation that depletion of the different DNMT genes including combinations that induce uPA in MCF-7 cells do not induce uPA in ZR-75-1 cells. The possibility that 5-azaCdR might have adverse effects on gene expression independent of DNA methylation, further underscore the potential advantage of gene-specific DNMT depletion over 5-azaCdR. Alternatively, DNA methylation outside the known promoter of uPA or DNA methylation of other genes that regulate uPA might be involved. However, the fact that different combinations of DNMT depletions did not induce uPA weakened the argument that uPA was regulated by DNA methylation in ZR-75-1 cells ( Figure 5A ). Nevertheless, DNMT3A must be involved in invasiveness of ZR-75 1 cells through methylation of other methylated genes since DNMT3A depletion does induce invasiveness in ZR-75-1 cells ( Figure 5B) .
One of the important differences between depletion of DNMT by siRNA and 5-azaCdR treatments is the extent of demethylation. Whereas 5-azaCdR triggers a massive general demethylation, triple DNMT depletion does not (Figure 3 ). Global demethylation is implicated in cancer and might play an important role in the adverse effects of DNA demethylating drugs. Our data suggests that it might be possible to bypass this risk by focusing on DNMT1-specific inhibitors.
What is the reason for this difference between the effects of the triple DNMT inhibition and 5-azaCdR on global DNA methylation? One possibility is that the triple siRNA depletion is not complete and that the extent of DNMT depletion is insufficient to cause global demethylation. However, the triple DNMT depletion is sufficient to induce cell invasiveness similar to 5-azaCdR ( Figures 1D and 5B) and to cause demethylation of CGs in the uPA and MMP2 promoter (Figure 3) . Therefore, this is not probably the case here. The second possibility is that since 5-azaCdR is known to incorporate into DNA during replication, adducts of aza-DNMT-DNA are formed at the replication forks (44) . These adducts induce DNA damage. Therefore, the observed growth inhibitory effect (Figure 2 ) might be part of the cell mechanisms to halt the cell cycle and attempt to repair such DNA damage. Indeed, we observed the characteristic G 2 M arrest in cell cycle after 5-azaCdR treatment (data not shown). Depleting DNMTs by siR-NA knockdown, on the other hand, does not lead to formation of these adducts. Depletion of DNMT1 was shown to inhibit DNA replication (36) and induce DNA stress checkpoints by mechanisms that differed from the mechanism induced by 5-azaCdR (49) . This DNA stress checkpoint might protect the cells from synthesizing DNA in the absence of DNMT activity limiting demethylation. Such a regulatory mechanism might not exist in response to 5-azaCdR resulting in extensive repair in the absence of DNMT activity. A third related explanation for the differences between 5-azaCdR and triple DNMTs depletion is that an additional mechanism of DNA demethylation is involved. The data presented in Figure 3A shows that demethylation in response to 5-azaCdR continues even after DNA synthesis has been brought to a halt. DNA repair mechanisms might be involved in demethylation in response to 5-azaCdR. An alternative possibility is that 5-azaCdR unleashes an active demethylation process. If indeed 5-azaCdR has a DNA replication-independent mechanism of DNA demethylation, this will have important implications. First, it extends the risk for toxicity from the rapidly growing tumor cells to the somatic non-dividing cells. Second, this suggests that DNMT inhibitors could possibly be used in non-dividing tissues such as the brain or heart.
In summary, we showed that it is possible to differentiate between pro-metastatic and growth related modes of action of the DNMT inhibitors. We also showed high level of selectivity at multiple levels in the cell. This suggests the possibility for selective combinations of DNMT inhibitors that will be used for different therapeutic modalities.
Supplementary material
Supplementary Figure 1 can be found at http://carcin.oxfordjournals .org/
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